- ICH GCP
- US Clinical Trials Registry
- Klinisk utprøving NCT02342574
F901318 Multiple Ascending Dose Study
F901318 - A Phase I, Double-Blind, Placebo Controlled, Single and Multiple Ascending Intravenous Dose, Safety, Tolerability and Pharmacokinetic Study in Healthy Male Subjects
Studieoversikt
Status
Forhold
Intervensjon / Behandling
Detaljert beskrivelse
Double blind, placebo controlled, ascending single and multiple intravenous dose, sequential group study. This will be a study in two parts. In the first part, up to twenty four subjects will complete the study in up to 3 cohorts (Groups A to C), each group consisting of 8 subjects, six of whom will receive active compound and two will receive placebo for eight days. Each subject will be on study for approximately 7 weeks. Each subject will participate in one treatment cohort only, residing at the Clinical Research Unit (CRU) from Day -1 (the day before dosing) to Day 13 (120 hours post the last dose).
This first part (Part 1) will test doses already evaluated in the previous single ascending dose study (F901318-01-01-14, 0.25-4 mg/kg given over 4 hours). The dose levels for the study are expected to be 1.5, 3 and 4 mg/kg/day given as a four hour infusion once daily.
In the second part of the study (Part 2), doses higher than those previously evaluated may be studied and/or different dosing schedules designed to deliver a maximum tolerated dose over 24 hours. If a dose level higher than those previously studied is chosen, there will be an optional single dose studied initially for safety and pharmacokinetic profile (Part 2A), followed about 14 days later in another group of subjects by exposure at that same dose level over 8 consecutive days (Part 2B). These higher doses may be given in a once or twice daily dosing schedule. Six subjects will receive active compound and two will receive placebo in both the single dose and multiple dose cohorts. The single dose cohorts will receive study drug in a sentinel group design in which two subjects receive study drug (one active and one placebo) on the first day and the rest of the group one day later. There will be a review of safety data by the Principal Investigator and the Medical Monitor after the first two subjects have been dosed and before the last six subjects are dosed in each cohort in part 2A.
In Part 2, up to forty-eight subjects will complete the study in up to 6 cohorts (Part 2A, Groups D1 to F1, single day dosing, and Part 2B, Groups D2 to F2 eight days' dosing). Subjects in Parts 1 and 2B will be on the study for approximately 7 weeks and Part 2A for approximately 8 weeks. Each subject will participate in one treatment cohort only, residing at the Clinical Research Unit (CRU) from Day -1 (the day before dosing) to Day 6 (120 hours after the single dose in Parts 1 and 2A) and from Day -1 (the day before dosing) to Day 13 (120 hours after the first dose in Part 2B). The proposed total daily dose levels for Part 2 will be up to 10 mg/kg/day given either once daily or in two split daily doses. The duration of the infusions will be between 2 and 24 hours which may include a loading dose to achieve therapeutic plasma concentrations as quickly as possible.
All subjects will return for a post-study visit 8 to 10 days after the last dose of study medication.
Studietype
Registrering (Faktiske)
Fase
- Fase 1
Kontakter og plasseringer
Studiesteder
-
-
UK
-
London, UK, Storbritannia, NW10 7EW
- Hammersmith Medicines Research
-
-
Deltakelseskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Subjects will be males of any ethnic origin between 18 and 45 years of age and weighing 60-100 kg inclusive
- Subjects must be in good health, as determined by a medical history, physical examination, 12-lead electrocardiogram (ECG) and clinical laboratory evaluations (congenital non haemolytic hyperbilirubinaemia is acceptable)
- Subjects will have given their written informed consent to participate in the study and to abide by the study restrictions
- Subjects must have ophthalmology assessments within the normal limits at screening. This includes normal Meibomian gland function
Exclusion Criteria:
- Male subjects who are not willing to use appropriate contraception (such as a condom) during the study and until follow up
- Subjects who have received any prescribed systemic or topical medication within 14 days of dosing with study drug unless in the opinion of the Investigator and the Medical Monitor the medication will not interfere with the study procedures or compromise safety
- Subjects who have used any non-prescribed systemic or topical medication (including herbal remedies) within 7 days of dosing with study drug (with the exception of vitamin/mineral supplements and paracetamol) unless in the opinion of the Investigator and the Medical Monitor the medication will not interfere with the study procedures or compromise safety
- Subjects who have received any medications, including St John's Wort, known to chronically alter drug absorption or elimination processes within 30 days of dosing with study drug unless in the opinion of the Investigator and the Medical Monitor the medication will not interfere with the study procedures or compromise safety
- Subjects who are still participating in a clinical study (e.g. attending follow-up visits) or who have participated in a clinical study involving administration of an investigational drug (new chemical or biological entity) in the past 3 months since the last dose.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Behandling
- Tildeling: Randomisert
- Intervensjonsmodell: Parallell tildeling
- Masking: Trippel
Våpen og intervensjoner
Deltakergruppe / Arm |
Intervensjon / Behandling |
---|---|
Eksperimentell: A active
Six subjects receiving F901318 1.5 mg/kg intravenously for eight days
|
Administration of active compound
|
Placebo komparator: A placebo
Two subjects receiving F901318 placebo intravenously for eight days
|
Administrering av placebo
|
Eksperimentell: B active
Six subjects receiving F901318 3 mg/kg intravenously for eight days
|
Administration of active compound
|
Placebo komparator: B placebo
Two subjects receiving F901318 placebo intravenously for eight days
|
Administrering av placebo
|
Eksperimentell: C active
Six subjects receiving F901318 4 mg/kg intravenously for eight days
|
Administration of active compound
|
Placebo komparator: C placebo
Two subjects receiving F901318 placebo intravenously for eight days
|
Administrering av placebo
|
Eksperimentell: D1 active
Six subjects dosed for one day with F901318 intravenously dose to be determined
|
Administration of active compound
|
Placebo komparator: D1 placebo
Two subjects receiving F901318 placebo intravenously for one day
|
Administrering av placebo
|
Eksperimentell: E1 active
Six subjects dosed for one day with F901318 intravenously dose to be determined
|
Administration of active compound
|
Placebo komparator: E1 placebo
Two subjects receiving F901318 placebo intravenously for one day
|
Administrering av placebo
|
Eksperimentell: F1 active
Six subjects dosed for one day with F901318 intravenously dose to be determined
|
Administration of active compound
|
Placebo komparator: F1 placebo
Two subjects receiving F901318 placebo intravenously for one day
|
Administrering av placebo
|
Eksperimentell: D2 active
Six subjects dosed for eight days with F901318 intravenously dose to be determined
|
Administration of active compound
|
Placebo komparator: D2 placebo
Two subjects receiving F901318 placebo intravenously for eight days
|
Administrering av placebo
|
Eksperimentell: E2 active
Six subjects dosed for eight days with F901318 intravenously dose to be determined
|
Administration of active compound
|
Placebo komparator: E2 placebo
Two subjects receiving F901318 placebo intravenously for eight days
|
Administrering av placebo
|
Eksperimentell: F2 active
Six subjects dosed for eight days with F901318 intravenously dose to be determined
|
Administration of active compound
|
Placebo komparator: F2 placebo
Two subjects receiving F901318 placebo intravenously for eight days
|
Administrering av placebo
|
Hva måler studien?
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
safety: adverse events
Tidsramme: 13 days
|
adverse events
|
13 days
|
Sekundære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
---|---|---|
pharmacokinetics AUC
Tidsramme: 13 days
|
area under concentration time curve
|
13 days
|
pharmacokinetics Cmin
Tidsramme: 13 days
|
drug level in blood 24 hours after dosing
|
13 days
|
Samarbeidspartnere og etterforskere
Sponsor
Samarbeidspartnere
Etterforskere
- Hovedetterforsker: Frans van den Berg, MB ChB, Hammersmith Medicines Research
Studierekorddatoer
Studer hoveddatoer
Studiestart
Primær fullføring (Faktiske)
Studiet fullført (Faktiske)
Datoer for studieregistrering
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Anslag)
Oppdateringer av studieposter
Sist oppdatering lagt ut (Anslag)
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Ytterligere relevante MeSH-vilkår
Andre studie-ID-numre
- F901318-01-02-14
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .
Kliniske studier på Invasiv aspergillose
-
Universitätsklinikum Hamburg-EppendorfRekrutteringSerratus Anterior Plane Block | Minimal invasiv hjertekirurgi | Minimal invasiv hjertekirurgi MitralklaffkirurgiTyskland
-
Algemeen Ziekenhuis Maria MiddelaresFullførtUtskifting av aortaklaffen | Mitralklaffkirurgi | Minimal invasiv hjertekirurgi | Minimal invasiv direkte koronararteriebypassBelgia
-
Melbourne HealthMerck Sharp & Dohme LLCRekrutteringSoppinfeksjon | Farmakokinetikk | Invasiv aspergillose | Profylakse | Invasive candidiaser | Posakonazol | Invasiv mykoseAustralia
-
CSPC ZhongQi Pharmaceutical Technology Co., Ltd.UkjentInvasiv aspergillose | Invasiv candidiasis
-
Duke UniversityNational Institute of Allergy and Infectious Diseases (NIAID); Children...FullførtPediatrisk invasiv candidiasisForente stater, Colombia, Canada, India, Saudi-Arabia, Hellas, Italia, Spania
-
CSPC Ouyi Pharmaceutical Co., Ltd.Har ikke rekruttert ennåInvasiv aspergillose | Invasiv candidiasisKina
-
AllerganFullførtIkke-invasiv fettreduksjonForente stater, Frankrike, Singapore, Sverige, Tyskland
-
Alexandria UniversityFullført
-
Chongqing Medical UniversityFullført
-
Fundació Institut de Recerca de l'Hospital de la...Sociedad Española de Neumología y Cirugía Torácica; Societat Catalana de...RekrutteringIkke-invasiv ventilasjonSpania
Kliniske studier på Placebo
-
SamA Pharmaceutical Co., LtdUkjentAkutt bronkitt | Akutt øvre luftveisinfeksjonKorea, Republikken
-
National Institute on Drug Abuse (NIDA)FullførtCannabisbrukForente stater
-
AstraZenecaParexel; Spandauer Damm 130; 14050; Berlin, GermanyFullførtMannlige personer med type II diabetes (T2DM)Tyskland
-
Heptares Therapeutics LimitedFullførtFarmakokinetikk | SikkerhetsproblemerStorbritannia
-
Regado Biosciences, Inc.FullførtFrivillig friskForente stater
-
Texas A&M UniversityNutraboltFullførtGlucose and Insulin Response
-
Longeveron Inc.AvsluttetHypoplastisk venstre hjertesyndromForente stater
-
ItalfarmacoFullførtBecker muskeldystrofiNederland, Italia
-
Instituto de Investigación Hospital Universitario...Creaciones Aromáticas Industriales, S.A. (CARINSA)Fullført